Retina (Philadelphia, Pa.) · 2026
SAFETY AND OUTCOME OF TRANSSCLERAL FINE-NEEDLE ASPIRATION BIOPSY IN UVEAL MELANOMA: 10-year Experience in 347 Cases.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bourdin Alexandre, Dureau Sylvain, Algret Nathalie, Malaise Denis, Lumbroso-Le Rouic Livia, Pierron Gaëlle, Aït Rais Khadija, Belkacem Anas, Piperno-Neumann Sophie, Rodrigues Manuel, Cassoux Nathalie, Matet Alexandre
Аннотация
PURPOSE: To report safety outcomes of transscleral fine-needle aspiration biopsy (FNAB) followed by irradiation for uveal melanoma (UM) in a tertiary ocular oncology center over 10 years, and assess whether FNAB modified the overall prognosis of patients treated for primary UM.
METHODS: Patients treated for UM between 2009 and 2020, eligible for conservative treatments by proton beam radiotherapy or Iodine-125 brachytherapy and to FNAB performed before UM treatment (tumor thickness 5-10 mm), were included retrospectively. Patients who underwent FNAB were compared with nonbiopsied UM controls with similar characteristics, matched 1:1 using a propensity score. Complication rates, including local intraocular and extraocular relapse, metastases, and overall survival, were analyzed.
RESULTS: Among 2,813 UM cases, 347 cases who underwent FNAB were matched to 347 controls. The median follow-up was 6.1 years (min = 0.2-max=13.3). There was no difference in overall survival (OS) ( P = 0.25) and metastasis-free interval (MFI, P = 0.68). Twenty-four cases (6.9%) and 17 controls (4.9%) developed local intraocular recurrence ( P = 0.46). Extraocular relapses occurred in five cases (1.4%) and one control (0.3%), showing no statistical difference ( P = 0.12). Patients with monosomy 3 and chromosome 8 gain had significantly worse OS and MFI compared with those with normal 3 and 8 chromosomes, and to a lesser extent to those with either chromosomal alteration ( P < 0.0001). Those with monosomy 3 and chromosome 8 gain experienced more local recurrences ( P = 0.013).
CONCLUSION: FNAB seems safe in extraocular relapses, OS or MFI, but over the 2009 to 2020 period, accessing to primary UM somatic genetic features did not improve patient prognosis.
METHODS: Patients treated for UM between 2009 and 2020, eligible for conservative treatments by proton beam radiotherapy or Iodine-125 brachytherapy and to FNAB performed before UM treatment (tumor thickness 5-10 mm), were included retrospectively. Patients who underwent FNAB were compared with nonbiopsied UM controls with similar characteristics, matched 1:1 using a propensity score. Complication rates, including local intraocular and extraocular relapse, metastases, and overall survival, were analyzed.
RESULTS: Among 2,813 UM cases, 347 cases who underwent FNAB were matched to 347 controls. The median follow-up was 6.1 years (min = 0.2-max=13.3). There was no difference in overall survival (OS) ( P = 0.25) and metastasis-free interval (MFI, P = 0.68). Twenty-four cases (6.9%) and 17 controls (4.9%) developed local intraocular recurrence ( P = 0.46). Extraocular relapses occurred in five cases (1.4%) and one control (0.3%), showing no statistical difference ( P = 0.12). Patients with monosomy 3 and chromosome 8 gain had significantly worse OS and MFI compared with those with normal 3 and 8 chromosomes, and to a lesser extent to those with either chromosomal alteration ( P < 0.0001). Those with monosomy 3 and chromosome 8 gain experienced more local recurrences ( P = 0.013).
CONCLUSION: FNAB seems safe in extraocular relapses, OS or MFI, but over the 2009 to 2020 period, accessing to primary UM somatic genetic features did not improve patient prognosis.